Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity*

Hideyuki Sakoda {ddagger}, Yukiko Gotoh §, Hideki Katagiri ¶, Mineo Kurokawa ||, Hiraku Ono {ddagger}, Yukiko Onishi {ddagger}, Motonobu Anai {ddagger}, Takehide Ogihara ||, Midori Fujishiro ||, Yasushi Fukushima ||, Miho Abe ||, Nobuhiro Shojima ||, Masatoshi Kikuchi {ddagger}, Yoshitomo Oka ¶, Hisamaru Hirai || and Tomoichiro Asano || **

From the {ddagger}Institute for Adult Diseases, Asahi Life Foundation, 1-9-14 Nishishinjuku, Shinjuku-ku, Tokyo 116, Japan, the ||Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan, the §Department of Molecular Biology, Institute of Molecular and Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan, and the Division of Molecular Metabolism and Diabetes, Department of Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryou, Aoba-ku, Sendai 980-8575, Japan

Received for publication, February 3, 2003 , and in revised form, April 30, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Serum- and glucocorticoid-regulated kinase (SGK) is a serine kinase that has a catalytic domain homologous to that of Akt, but lacks the pleckstrin homology domain present in Akt. Akt reportedly plays a key role in various cellular actions, including glucose transport, glycogen synthesis, DNA synthesis, anti-apoptotic activity, and cell proliferation. In this study, we attempted to reveal the different roles of SGK and Akt by overexpressing active mutants of Akt and SGK. We found that adenovirus-mediated overexpression of myristoylated (myr-) forms of Akt resulted in high glucose transport activity in 3T3-L1 adipocytes, phosphorylated glycogen synthase kinase-3 (GSK3) and enhanced glycogen synthase activity in hepatocytes, and the promotion of DNA synthesis in interleukin-3-dependent 32D cells. In addition, stable transfection of myr-Akt in NIH3T3 cells induced an oncogenic transformation in soft agar assays. The active mutant of SGK (D-SGK, substitution of Ser422 with Asp) and myr-SGK were shown to phosphorylate GSK3 and to enhance glycogen synthase activity in hepatocytes in a manner very similar to that observed for myr-Akt. However, despite the comparable degree of GSK3 phosphorylation between myr-Akt and D-SGK or myr-SGK, D-SGK and myr-SGK failed to enhance glucose transport activity in 3T3-L1 cells, DNA synthesis in 32D cells, and oncogenic transformation in NIH3T3 cells. Therefore, the different roles of SGK and Akt cannot be attributed to ability or inability to translocate to the membrane thorough the pleckstrin homology domain, but rather must be attributable to differences in the relatively narrow substrate specificities of these kinases. In addition, our observations strongly suggest that phosphorylation of GSK3 is either not involved in or not sufficient for GLUT4 translocation, DNA synthesis, or oncogenic transformation. Thus, the identification of substrates selectively phosphorylated by Akt, but by not SGK, may provide clues to clarifying the pathway leading from Akt activation to these cellular activities.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
PI1 3-kinase has been implicated in the regulation of numerous cellular processes (13). The lipid product of PI 3-kinase reportedly activates several AGC kinases, including Akt, atypical protein kinases C, p70 S6 kinase, and SGK (3, 45). Among these AGC kinases, Akt was found to mediate various insulin- and growth factor-induced cellular responses such as stimulation of GLUT4 translocation to the plasma membrane (10, 11, 46, 47), inhibition of GSK3 (22), and promotion of cell survival by inhibiting apoptosis (48). In addition, as shown by the v-Akt data, constitutively activated Akt has transforming activity (9). These cellular activities have been shown to be induced by overexpression of constitutively activated Akt or its membrane-targeted mutant. For example, glucose uptake is reportedly increased in both constitutively activated Akt-overexpressing 3T3-L1 adipocytes and L6 myotubes (10, 11), whereas Akt2-deficient mice show impaired glucose tolerance due to decreased insulin-induced glucose uptake in skeletal muscle and increased hepatic glucose production (12).

On the other hand, SGK, the expression level of which is increased by glucocorticoid and serum stimulation in cultured cells (13, 48), is the one member of the AGC kinase family with a highly conserved kinase domain compared with that of Akt (54% identical amino acids) (14, 15). Indeed, the substrate specificity of the kinase domain of SGK has been reported to be similar to that of Akt (16). Furthermore, it was also reported that the PI 3-kinase pathway activates SGK through PDK1/2, i.e. in the same manner as for Akt (17, 49). However, the most apparent difference in the structures of SGK and Akt is that SGK lacks the PH domain that Akt has. Thus, SGK is considered to not be able to translocate to the membrane like Akt in response to growth factor stimulation. In fact, it was reported that insulin stimulation induces the translocation of Akt to the membrane fraction, but that this does not occur with mutant Akt lacking the PH domain or with SGK (18).

Although recent studies revealed a possible role of SGK in aldosterone-induced apical translocation of the epithelial sodium channel in distal nephrons (1921), it seems that our understanding of the roles of SGK remains limited. In this study, we investigated whether SGK induces the cellular functions known to be induced by activated Akt. Akt activation reportedly plays a key role in glucose metabolism, including increased glycogen synthase and GLUT4 translocation to the plasma membrane, as well as in inhibition of apoptosis and promotion of cell growth. The induction of these cellular functions by Akt has been well demonstrated, and they are also induced by overexpressing myr-Akt (10, 11, 22). Thus, we constructed the active mutant of SGK and myr-SGK and investigated whether these SGK mutants can exert the same actions as myr-Akt.

This is the first report clearly demonstrating the different roles of Akt and SGK. In addition, interestingly, these differences are attributable not to the presence or absence of the PH domain responsible for membrane targeting, but very possibly to differences in the substrate specificities of the kinase domains of SGK and Akt.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies—Anti-Myc tag (clone 9E10), anti-phospho-Ser21 GSK3{alpha}, and anti-SGK antibodies were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-Akt and anti-phospho-Ser473 Akt antibodies were purchased from Cell Signaling Technology (Beverly, MA).

Cell Culture—Hepatocytes were isolated from fasted rats by collagenase perfusion as described previously (23) and plated in collagen-coated 25-cm2 flasks at a density of 1.0 x 105 cells/cm2 in DMEM supplemented with 10% FCS, 0.5 µg/ml insulin, 1 µM dexamethasone, and 10 ng/ml epidermal growth factor. After a 6-h attachment period, hepatocytes were transfected using adenoviral gene transfer. 3T3-L1 fibroblasts were maintained in DMEM supplemented with 10% donor calf serum (Invitrogen) under a 10% CO2 atmosphere at 37 °C. 2 days after the fibroblasts reached confluence, differentiation was induced by incubating the cells for 48 h in DMEM supplemented with 10% fetal bovine serum, 0.5 mmol/liter 3-isobutyl-1-methylxanthine, and 4 mg/ml dexamethasone. Thereafter, the cells were maintained in DMEM supplemented with 10% fetal bovine serum for an additional 4–10 days; once >90% of the cells expressed the adipocyte phenotype, the cells were used for experimentation. 32D cells were maintained in RPMI 1640 medium with 10% FCS and 0.25 ng/ml murine IL-3 (24). NIH3T3 cells were maintained in DMEM with 10% FCS. Each cDNA was transfected into NIH3T3 cells with an expression vector (pCAGGs), and the permanently expressing clones were selected in DMEM containing 500 mg/liter Geneticin.

Construction of SGK Mutants and myr-Akt—3A-SGK, a dominant-negative form of SGK, was constructed by substituting lysine 127, threonine 256, and serine 422 with alanines. D-SGK was constructed by substituting serine 422 with aspartic acid. myr-SGK contains an src myristoylation signal sequence at the N terminus. MAA-Akt, a dominant-negative form of Akt, was constructed by substituting lysine 179, threonine 308, and serine 473 with alanines. myr-Akt, which contains an src myristoylation signal sequence, was described previously (25). All the constructs were designed to contain a Myc tag at the C terminus, and their structures are shown in Fig. 1. Recombinant adenoviruses were generated, purified, and concentrated using cesium chloride ultracentrifugation as reported previously (26, 27). Equal amounts of Akt and SGK were overexpressed throughout all of the experiments.



View larger version (34K):
[in this window]
[in a new window]
 
FIG. 1.
Schematic presentation of recombinant adenoviruses of Akt and SGK. 3A-SGK was constructed by substituting lysine 127, threonine 256, and serine 422 with alanines. D-SGK was constructed by substituting serine 422 with aspartic acid. myr-SGK and myr-Akt contain an src myristoylation signal sequence (myr) at the N terminus. MAA-Akt was constructed by substituting lysine 179, threonine 308, and serine 473 with alanines. All constructs were designed to contain a Myc tag at the C terminus. a.a., amino acids.

 

Gene Transfer into Each Cell Type—For gene transfer into hepatocytes, cells were incubated for 1 h at 37 °C in DMEM containing 1.0 x 108 plaque-forming units/ml recombinant adenovirus, after which the virus-containing medium was replaced with normal growth medium. Glycogen synthase assays were performed 36 h later. For gene transfer into 3T3-L1 adipocytes, cells were incubated for 6 h at 37 °C in DMEM containing recombinant adenovirus. Experiments were performed 2 days later. 32D cells were incubated for 6 h at 37 °C in RPMI 1640 medium containing recombinant adenovirus. 24 h after adenoviral gene transfer, the cells were IL-3-starved for an additional 24 h, and then DNA synthesis assays were performed. In 3T3-L1 adipocytes and 32D cells, all recombinant adenoviruses were used at a concentration of 3.0 x 109 plaque-forming units/ml. Under these conditions, none of the cells infected with LacZ exhibited significant differences in glycogen synthesis or glucose transport activity compared with non-infected cells, and 95~100% of the cells were infected as judged by blue coloration after 5-bromo-4-chloro-3-indolyl-{beta}-D-galactopyranoside (X-gal) incubation 36~48 h after infection.

Immunoprecipitation and Immunoblotting—The cells were collected and boiled in Laemmli sample buffer containing 100 mmol/liter dithiothreitol. SDS-PAGE and immunoblotting were performed as described previously (27) using each antibody as a probe.

Glycogen Synthase Assay—After 3 h of serum starvation, cells in 25-cm2 flasks were stimulated with or without 100 nM insulin for 30 min. The cells were homogenized in homogenizing buffer containing 50 mM Tris, 10 mM EDTA, and 100 mM NaF. 50 µg of liver samples were then assayed in glycogen synthase buffer containing 8.9 mM UDP-[6-3H]glucose (1 Ci/mmol) in the absence or presence of 10 mM Glu-6-P for 20 min at 30 °C. UDP-[6-3H]glucose incorporation into glycogen was measured by liquid scintillation counting.

Glucose Transport Assay—3T3-L1 adipocytes in 24-well culture dishes were serum-starved for 3 h in DMEM containing 0.2% bovine serum albumin. They were next incubated for 45 min in glucose-free Krebs-Ringer phosphate buffer (137 mM NaCl, 4.7 mM KCl, 10 mM sodium phosphate (pH 7.4), 0.5 mM MgCl2, and 1 mM CaCl2) and then incubated with or without 100 nM insulin for 15 min. Basal and stimulated uptakes of 2-deoxy-D-[3H]glucose were then measured as described previously (28).

DNA Synthesis Assay—32D cells were maintained in RPMI 1640 medium supplemented with 10% FCS and 0.25 ng/ml IL-3. After incubation in IL-3-free RPMI 1640 medium for 24 h, the cells were incubated with BrdUrd labeling solution for 6 h. BrdUrd incorporation was measured using the BrdUrd labeling and detection kit III (Roche Applied Science) (44).

Soft Agar Assays—For the soft agar assay, cells of each transfected derivative were trypsinized, suspended in DMEM containing 0.3% agar and 20% FCS, and plated onto a bottom layer containing 0.6% agar. Cells were plated at a density of 2 x 104 cells/3.5-cm dish, and colonies >0.5 mm in diameter were counted after 14 days (29). All procedures were performed in three independent experiments, and similar results were obtained.

Statistical Analysis—Results are expressed as means ± S.E. Comparisons were made using unpaired Student's t test. Values of p <0.05 were considered statistically significant.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Effect of SGK or Akt Overexpression on Glucose Transport— WT-Akt, MAA-Akt, myr-Akt, WT-SGK, 3A-SGK, and myr-SGK were overexpressed in 3T3-L1 adipocytes. Immunoblotting with anti-Myc tag antibody revealed the expression levels of Akt and SGK and their mutants to be comparable (Fig. 2A, first panel). In addition, the expression levels of WT-Akt, MAA-Akt, and myr-Akt were approximately five times those of endogenously expressed Akt judging from the immunoblotting results using anti-Akt antibody (Fig. 2A, second panel), and basal phosphorylation was observed in myr-Akt (third panel). On the other hand, endogenously expressed SGK was not detectable in 3T3-L1 adipocytes, whereas overexpressed WT-SGK, 3A-SGK, and myr-SGK were detected by immunoblotting (Fig. 2A, fourth panel). Increased phosphorylation of GSK3 was observed in 3T3-L1 adipocytes overexpressing myr-Akt, D-SGK, and myr-SGK, whereas overexpression of wild-type and dominant-negative mutants of Akt and SGK did not increase GSK3 phosphorylation (Fig. 2A, fifth panel). Finally, interestingly, although 2-deoxy-D-[3H]glucose uptake into 3T3-L1 adipocytes was increased 8-fold by overexpression of myr-Akt compared with that of LacZ, D-SGK or myr-SGK overexpression had essentially no effect on 2-deoxy-D-[3H]glucose uptake (Fig. 2B).



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 2.
2-Deoxy-D-[3H]glucose uptake by Akt- or SGK-overexpressing 3T3-L1 adipocytes. A, after 3 h of serum starvation, cells overexpressing LacZ, Akt, or SGK were washed twice with cold phosphate-buffered saline. 3T3-L1 cells were then lysed and boiled in Laemmli buffer. Western blotting was performed using anti-Myc (first panel), anti-Akt (second panel), anti-phospho-Ser473 Akt (pAkt; third panel), anti-SGK (fourth panel), and anti-phospho-Ser21 GSK3{alpha} (pGSK3; fifth panel) antibodies. B, after 3 h of serum starvation, cells overexpressing LacZ, Akt, or SGK were incubated in glucose-free Krebs-Ringer phosphate buffer for 45 min. The cells were then incubated with or without 100 nM insulin (Ins) for 15 min, and 2-deoxy-D-[3H]glucose (2DG) uptake was measured. Bars depict means ± S.E. of three independent experiments. IB, immunoblot.

 

Effect of SGK or Akt Overexpression on Phosphorylation of GSK3 and Glycogen Synthesis—To confirm that phosphorylated GSK3 elevates glycogen synthesis irrespective of whether Akt or SGK phosphorylates GSK3, active mutants of Akt (myr-Akt) and SGK (D-SGK and myr-SGK) were overexpressed in primary cultured rat hepatocytes. The expression levels of myr-Akt, D-SGK, and myr-SGK were comparable, as shown by immunoblotting using anti-Myc tag antibody (Fig. 3A). Similar to the observations in 3T3-L1 adipocytes, overexpression of these active mutants of Akt and SGK induced an apparent increase in phosphorylation of GSK3, as did insulin stimulation (Fig. 3B). As shown in Fig. 3C, glycogen synthase activity was shown to be significantly increased (~1.5-fold) either by 30 min of stimulation with insulin or by overexpression of myr-Akt, D-SGK, or myr-SGK compared with the control. Thus, it is clear that phosphorylation of GSK3 results in the elevation of glycogen synthesis irrespective of phosphorylation by either Akt or SGK.



View larger version (54K):
[in this window]
[in a new window]
 
FIG. 3.
Phosphorylation of GSK3 and glycogen synthesis in primary cultured rat hepatocytes. A and B, after 3 h of serum starvation, cells were stimulated with or without 100 nM insulin for 30 min. The cells were washed twice with cold phosphate-buffered saline and then lysed and boiled. Western blotting was performed using anti-Myc (A) and anti-phospho-Ser21 GSK3{alpha} (pGSK3; B) antibodies. C, the cells were homogenized in homogenizing buffer. The lysate was then assayed in glycogen synthase buffer in the absence and presence of 10 mM Glu-6-P (G6P) for 20 min at 30 °C. UDP-[6-3H]glucose incorporation into glycogen was measured by liquid scintillation counting. Bars depict means ± S.E. of three independent experiments. IB, immunoblot.

 

Effect of SGK or Akt Overexpression on DNA Synthesis—WT-Akt, MAA-Akt, myr-Akt, WT-SGK, 3A-SGK, and myr-SGK were overexpressed in 32D cells by adenoviral transfer so that their expression levels were similar (Fig. 4A), and the effects on DNA synthesis were examined by measuring BrdUrd incorporation. Because 32D is an IL-3-dependent cell line, removal of IL-3 from the medium reportedly induces apoptosis, which can be shown to be the result of suppressed DNA synthesis. Overexpression of myr-Akt, D-SGK, and myr-SGK induced GSK3 phosphorylation to a similar degree, whereas that of WT-Akt, MAA-Akt, WT-SGK, and 3A-SGK did not (Fig. 4B). However, interestingly, overexpression of only myr-Akt significantly enhanced the protection from apoptosis achieved by lack of IL-3 (Fig. 4C). On the other hand, overexpression of D-SGK or myr-SGK had no inhibitory effect on apoptosis, despite phosphorylation of GSK3.



View larger version (38K):
[in this window]
[in a new window]
 
FIG. 4.
DNA synthesis in 32D cells. A and B, 32D cells were maintained in RPMI 1640 medium supplemented with 10% FCS and 0.25 ng/ml IL-3. 48 h after adenoviral transfer, SDS-PAGE and Western blotting were performed using anti-Myc (A) and anti-phospho-Ser21 GSK3{alpha} (pGSK3; B) antibodies. C, after incubation in IL-3-free RPMI 1640 medium for 24 h, the cells were incubated with BrdUrd labeling solution for 6 h. BrdUrd incorporation was measured using the BrdUrd labeling and detection kit III. Bars depict means ± S.E. of three independent experiments. IB, immunoblot.

 

myr-Akt Overexpression Alone Can Transform NIH3T3 Cells—Finally, we analyzed the transforming ability of Akt and SGK by evaluating the capacity for anchorage-independent growth. NIH3T3 cells stably transfected with either Akt or SGK constructs were seeded in DMEM containing 0.3% agar and 20% FCS, and colony formation was estimated as a representative of anchorage-independent growth ability. Three independent experiments were performed using three different clones of each derivative, and a representative one is shown in Fig. 5 (A and B). Stable expression of Akt and SGK constructs was confirmed by immunoblotting with anti-Myc tag, anti-Akt, and anti-SGK antibodies (Fig. 5B). Similar to observations in cells transiently overexpressing Akt or SGK due to adenoviral transfer, stable overexpression of myr-Akt, D-SGK, and myr-SGK significantly increased the phosphorylation level of GSK3, whereas that of other constructs did not. These cells were subjected to soft agar assay to evaluate their transforming activity. As shown in Fig. 5B (middle panel), myr-Akt-expressing cells formed many macroscopic colonies within 14 days after being seeded. In contrast, although D-SGK- and myr-SGK-expressing cells showed phosphorylation of GSK3, they apparently could not make colonies (Fig. 5B, upper and lower panels). The colonies (counted from the three independent clones for each of the Akt and SGK constructs) are shown as bar graphs in Fig. 5C.



View larger version (51K):
[in this window]
[in a new window]
 
FIG. 5.
Soft agar assays demonstrating transformation of NIH3T3 fibroblasts by Akt and SGK. A, NIH3T3 cells stably transfected with either Akt or SGK constructs were lysed and boiled in Laemmli buffer. Western blotting was performed using anti-Myc (first panel), anti-Akt (second panel), anti-phospho-Ser473 Akt (pAkt; third panel), anti-SGK (fourth panel), and anti-phospho-Ser21 GSK3{alpha} (pGSK3; fifth panel) antibodies. B and C, for the soft agar assay, cells of each transfected derivative were trypsinized, suspended in DMEM containing 0.3% agar and 20% FCS, and plated onto a bottom layer containing 0.6% agar. Cells were plated at a density of 2 x 104 cells/3.5-cm dish. myr-Akt-expressing cells (but not other transfectants) made macroscopic colonies (B). Colonies >0.5 mm in diameter were counted after 14 days (C). Three independent experiments were performed using three different clones of each derivative, and similar results were obtained. IB, immunoblot.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Numerous serine/threonine kinases exist in the cell, and they play specific roles by inducing individual cellular functions. As to the molecular mechanisms underlying the various roles of each kinase protein, the substrate specificity of the kinase domain and subcellular distribution are considered to be major contributors. SGK and Akt are considered to be very similar kinase proteins, both of which belong to the AGC family. They are activated via phosphorylation by PDK1 and PDK2, located downstream from PI 3-kinase. However, the presence and absence of a PH domain in Akt and SGK, respectively, should result in different subcellular distributions of these two kinases. In the case of Akt, Akt translocates to the membrane fraction via binding of the PH domain with PI-3,4,5-P3 produced by PI 3-kinase, and phosphorylation of Thr306 and Ser473 of Akt by PDK1 and PDK2 takes place, thereby activating Akt kinase (3032). myr-Akt is located at the plasma membrane without stimulation and is constitutively activated (10, 33). Then, Akt phosphorylates several substrates that transmit signals (6).

In this study, to investigate the different roles of Akt and SGK, active as well as membrane-targeted active mutants of these kinases were overexpressed. Previous studies have established the functions induced by and the roles of activated Akt, and all or most of these cellular actions, for which Akt is reportedly responsible, are indeed induced by overexpression of myr-Akt (3337). Thus, although this study was carried out employing an overexpression system, the cellular actions described herein are considered to be physiological functions induced by Akt. For example, it is well established that Akt plays a major role in glucose metabolism, including increased glycogen synthase and GLUT4 translocation to the plasma membrane, functions that can be induced by overexpressing myr-Akt (10, 11). Indeed, translocation of Akt to the plasma membrane is suggested to be important for glucose transport. In addition, the oncogenic activity of Akt is also well known since v-Akt has been identified as an oncogenic protein, and this promotion of cell growth activity is similarly observed upon overexpression of myr-Akt (38, 39).

We obtained two important conclusions from this comparative study of SGK and Akt mutants. The first is that SGK can mediate GSK3 phosphorylation and the resultant glycogen synthesis, but not other cellular functions induced by Akt such as increased glucose transport, inhibition of apoptosis, and oncogenic transformation. Thus, it is possible that increased expression of SGK inhibits the phosphorylation of Akt and the resultant cellular functions such as increased glucose transport, inhibition of apoptosis, and cell proliferation because these two kinases are similarly phosphorylated by PDK1 and PDK2. Conversely, an increase in SGK may contribute to increased glycogen synthesis by increasing the phosphorylation of GSK3. In addition, a previous report showed that overexpression of the myristoylated and PH domain-deleted form of Akt induces an increase in glucose transport activity in 3T3-L1 adipocytes (10). Therefore, these different roles of the two kinases are apparently not attributable to membrane-targeting ability or an unidentified mechanism of signal transduction from the PH domain, caused by the presence or absence of the PH domain, because myristoylated and PH domain-deleted Akt, but not myr-SGK, enhanced glucose transport, inhibition of apoptosis, and cell proliferation.

GSK3 is well established as a regulator of glycogen metabolism (22, 4042). Many proteins in this family are related to protein synthesis. Wnt signaling and transcription factors have been reported to be substrates of GSK3, and Somervaille et al. (43) described GSK3 and Bax as being involved in the suppression of apoptosis induced by growth factor withdrawal. However, our results suggest that GSK3 is very likely to be independent of Akt-induced cellular actions such as increased glucose transport, inhibition of apoptosis, and cell proliferation.

As discussed above, the different cellular functions induced by Akt and SGK cannot be attributed to the difference in membrane targeting through the PH domain. Although it has been reported that substrate specificities for synthetic peptides differ minimally between Akt and SGK based on an in vitro experiment using glutathione S-transferase fusion proteins and synthetic peptides (16), we speculate that considerable differences in terms of in vivo substrate specificity exist between these kinases, which account for the apparent differences in the roles of Akt and SGK. In other words, there may be some unidentified proteins phosphorylated by Akt, but not by SGK, that play key roles in glucose transport and anti-apoptotic effects, whereas GSK3 plays only minor roles in these functions.

In conclusion, we have demonstrated for the first time an important difference between Akt and SGK and that this difference is not due to membrane localization, but rather possibly to the difference in their kinase activities. The identification of substrates selectively phosphorylated by Akt, but not by SGK, may provide clues to clarifying the pathway leading from Akt activation to the aforementioned cellular activities.


    FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

** To whom correspondence should be addressed. Tel.: 81-3-3815-5411 (ext. 33133); Fax: 81-3-5803-1874; E-mail: asano-tky{at}umin.ac.jp.

1 The abbreviations used are: PI, phosphatidylinositol; SGK, serum- and glucocorticoid-regulated kinase; GLUT4, glucose transporter-4; GSK3, glycogen synthase kinase-3; PDK, phosphoinositide-dependent kinase; PH, pleckstrin homology; myr-, myristoylated; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; IL-3, interleukin-3; BrdUrd, bromodeoxyuridine; WT, wild-type. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kahn, C. R., and Folli, F. (1993) Horm. Res. (Basel) 39, Suppl. 3, 93–101[Medline] [Order article via Infotrieve]
  2. Egawa, K., Sharma, P. M., Nakashima, N., Huang, Y., Huver, E., Boss, G. R., and Olefsky, J. M. (1999) J. Biol. Chem. 274, 14306–14314[Abstract/Free Full Text]
  3. Cantley, L. C. (2002) Science 296, 1655–1657[Abstract/Free Full Text]
  4. Vivanco, I., and Sawyers, C. L. (2002) Nat. Rev. Cancer 2, 489–501[CrossRef][Medline] [Order article via Infotrieve]
  5. Blume-Jensen, P., and Hunter, T. (2001) Nature 411, 355–365[CrossRef][Medline] [Order article via Infotrieve]
  6. Vanhaesebroeck, B., and Alessi, D. R. (2000) Biochem. J. 346, 561–576[CrossRef][Medline] [Order article via Infotrieve]
  7. Corvera, S., and Czech, M. P. (1998) Trends Cell Biol. 8, 442–446[CrossRef][Medline] [Order article via Infotrieve]
  8. Hemmings, B. A. (1997) Science 275, 628–630[Free Full Text]
  9. Staal, S. P. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5034–5037[Abstract]
  10. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372–31378[Abstract/Free Full Text]
  11. Hajduch, E., Alessi, D. R., Hemmings, B. A., Hundal, H. S. (1998) Diabetes 47, 1006–1013[Abstract]
  12. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., III, Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Science 292, 1728–1731[Abstract/Free Full Text]
  13. Webster, M. K., Goya, L., Ge, Y., Maiyar, A. C., and Firestone, G. L. (1993) Mol. Cell. Biol. 13, 2031–2040[Abstract]
  14. Kobayashi, T., and Cohen, P. (1999) Biochem. J. 339, 319–328[CrossRef][Medline] [Order article via Infotrieve]
  15. Kobayashi, T., Deak, M., Morrice, N., and Cohen, P. (1999) Biochem. J. 344 Pt 1, 189–197[CrossRef][Medline] [Order article via Infotrieve]
  16. Casamayor, A., Torrance, P. D., Kobayashi, T., Thorner, J., and Alessi, D. R. (1999) Curr. Biol. 9, 186–197[CrossRef][Medline] [Order article via Infotrieve]
  17. Park, J., Leong, M. L., Buse, P., Maiyar, A. C., Firestone, G. L., and Hemmings, B. A. (1999) EMBO J. 18, 3024–3033[Abstract/Free Full Text]
  18. Sable, C. L., Filippa, N., Filloux, C., Hemmings, B. A., and Van Obberghen, E. (1998) J. Biol. Chem. 273, 29600–29606[Abstract/Free Full Text]
  19. Bhargava, A., Fullerton, M. J., Myles, K., Purdy, T. M., Funder, J. W., Pearce, D., and Cole, T. J. (2001) Endocrinology 142, 1587–1594[Abstract/Free Full Text]
  20. Chen, S. Y., Bhargava, A., Mastroberardino, L., Meijer, O. C., Wang, J., Buse, P., Firestone, G. L., Verrey, F., and Pearce, D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2514–2519[Abstract/Free Full Text]
  21. Verrey, F. (1999) Am. J. Physiol. 277, F319–F327[Medline] [Order article via Infotrieve]
  22. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785–789[CrossRef][Medline] [Order article via Infotrieve]
  23. Ogihara, T., Asano, T., Ando, K., Chiba, Y., Sakoda, H., Anai, M., Shojima, N., Ono, H., Onishi, Y., Fujishiro, M., Katagiri, H., Fukushima, Y., Kikuchi, M., Noguchi, N., Aburatani, H., Komuro, I., and Fujita, T. (2002) Hypertension 40, 872–879[Abstract/Free Full Text]
  24. Kurokawa, M., Mitani, K., Imai, Y., Ogawa, S., Yazaki, Y., and Hirai, H. (1998) Blood 92, 4003–4012[Abstract/Free Full Text]
  25. Sakoda, H., Ogihara, T., Anai, M., Funaki, M., Inukai, K., Katagiri, H., Fukushima, Y., Onishi, Y., Ono, H., Fujishiro, M., Kikuchi, M., Oka, Y., and Asano, T. (2000) Diabetes 49, 1700–1708[Abstract]
  26. Katagiri, H., Asano, T., Ishihara, H., Inukai, K., Shibasaki, Y., Kikuchi, M., Yazaki, Y., and Oka, Y. (1996) J. Biol. Chem. 271, 16987–16990[Abstract/Free Full Text]
  27. Sakoda, H., Ogihara, T., Anai, M., Fujishiro, M., Ono, H., Onishi, Y., Katagiri, H., Abe, M., Fukushima, Y., Shojima, N., Inukai, K., Kikuchi, M., Oka, Y., and Asano, T. (2002) Am. J. Physiol. 282, E1239–E1244
  28. Sakoda, H., Ogihara, T., Anai, M., Funaki, M., Inukai, K., Katagiri, H., Fukushima, Y., Onishi, Y., Ono, H., Yazaki, Y., Kikuchi, M., Oka, Y., and Asano, T. (1999) Diabetes 48, 1365–1371[Abstract]
  29. Kurokawa, M., Tanaka, T., Tanaka, K., Hirano, N., Ogawa, S., Mitani, K., Yazaki, Y., and Hirai H. (1996) J. Biol. Chem. 271, 16870–16876[Abstract/Free Full Text]
  30. Burgering, B. M., and Coffer, P. J. (1995) Nature 376, 599–602[CrossRef][Medline] [Order article via Infotrieve]
  31. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. (1996) EMBO J. 15, 6541–6551[Abstract]
  32. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261–269[Medline] [Order article via Infotrieve]
  33. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 31515–31524[Abstract/Free Full Text]
  34. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82–85[CrossRef][Medline] [Order article via Infotrieve]
  35. Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86–90[CrossRef][Medline] [Order article via Infotrieve]
  36. Meier, R., Alessi, D. R., Cron, P., Andjelkovic, M., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 30491–30497[Abstract/Free Full Text]
  37. Welch, H., Eguinoa, A., Stephens, L. R., and Hawkins, P. T. (1998) J. Biol. Chem. 273, 11248–11256[Abstract/Free Full Text]
  38. Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., and Vogt, P. K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14950–14955[Abstract/Free Full Text]
  39. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, S A., Jove, R., Tsichlis, P. N., Nicosia, S. V., and Cheng, J. Q. (2001) Am. J. Pathol. 159, 431–437[Abstract/Free Full Text]
  40. Frame, S., and Cohen, P. (2001) Biochem. J. 359, 1–16[CrossRef][Medline] [Order article via Infotrieve]
  41. Cohen, P., and Frame, S. (2001) Nat. Rev. Mol. Cell. Biol. 2, 769–776[CrossRef][Medline] [Order article via Infotrieve]
  42. Brady, M. J., Kartha, P. M., Aysola, A. A., and Saltiel, A. R. (1999) J. Biol. Chem. 274, 27497–27504[Abstract/Free Full Text]
  43. Somervaille, T. C., Linch, D. C., and Khwaja, A. (2001) Blood. 98, 1374–1381[Abstract/Free Full Text]
  44. Glowacki, J., Mizuno, S., and Greenberger, J. S. (1998) Cell Transplant. 7, 319–326[CrossRef][Medline] [Order article via Infotrieve]
  45. Czech, M. P., and Corvera, S. (1999) J. Biol. Chem. 274, 1865–1868[Free Full Text]
  46. Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., and Klip, A. (1999) Mol. Cell. Biol. 19, 4008–4018[Abstract/Free Full Text]
  47. Foster, L. J., Li, D., Randhawa, V. K., and Klip, A. (2001) J. Biol. Chem. 276, 44212–44221[Abstract/Free Full Text]
  48. Mizuno, H., and Nishida, E. (2001) Genes Cells 6, 261–268[Abstract/Free Full Text]
  49. Virbasius, J. V., Song, X., Pomerleau, D. P., Zhan, Y., Zhou, G. W., and Czech, M. P. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 12908–12913[Abstract/Free Full Text]